TuHURA Biosciences Inc (HURA) Stock Analysis

Verdict: AVOID

Severe cash burn with under 2 months of runway forces imminent share dilution despite Phase 3 immuno-oncology clinical milestones.

Investment score: 32/100

Analysis as of 2026-09-17

Is TuHURA Biosciences Inc stock worth reviewing? AI model thesis

The AI model assigns an AVOID recommendation due to an extreme liquidity shortfall ($3.62M cash vs -$27.71M annual cash burn) that makes severe share dilution inevitable.

7-factor investment score

Valuation: 20/100 (weight 20%)
Financial Health: 10/100 (weight 15%)
Technical Momentum: 45/100 (weight 15%)
Earnings Quality: 35/100 (weight 15%)
Insider Sentiment: 40/100 (weight 10%)
Analyst Consensus: 70/100 (weight 10%)
Risk-Adjusted Return: 25/100 (weight 15%)

TuHURA Biosciences Inc opportunities and risks

What speaks for HURA

FDA clearance of IND application for TBS-2025 VISTA-inhibiting antibody in AML

What speaks against HURA

Imminent cash cliff requiring emergency capital raise

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
HURA	n/a	0.0x	n/a	0.0%	0.0%	-22.6%
IMUX	n/a	0.0x	0.1x	0.0%	0.0%	-63.3%
CRBP	n/a	0.0x	n/a	0.0%	0.0%	-64.4%
CRBU	n/a	12.9x	n/a	-129.7%	-1030.4%	-74.0%
UNCY	n/a	0.0x	n/a	0.0%	0.0%	-21.7%
Peer median	n/a	0.0x	n/a	0.0%	0.0%	-63.9%

Frequently asked questions about TuHURA Biosciences Inc (HURA)

Is HURA stock a good investment?

The cached TradeMates AI model rates TuHURA Biosciences Inc as AVOID with an investment score of 32/100. The AI model assigns an AVOID recommendation due to an extreme liquidity shortfall ($3.62M cash vs -$27.71M annual cash burn) that makes severe share dilution inevitable. This is algorithmic model output, not personal investment advice.

Is HURA stock a buy?

The TradeMates model verdict for HURA is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.